Managing Bleeding Complications in Patients Treated with the Old and the New Anticoagulants

Author(s): Erica Romualdi, Elena Rancan, Sergio Siragusa, Walter Ageno

Journal Name: Current Pharmaceutical Design

Volume 16 , Issue 31 , 2010

Become EABM
Become Reviewer
Call for Editor


An increasing number of patients receive anticoagulant therapy to prevent and treat arterial or venous thromboembolism. The major complication of anticoagulant therapy is the increase of the individual bleeding risk. All anticoagulant drugs can cause haemorrhages, that can sometimes be life-threatening. Although heparins and the vitamin K antagonists have been the most widely used anticoagulants for decades, the correct management of bleeding complications associated with these agents has been poorly studied. More recently, new anticoagulant drugs, both parenteral and oral, have been approved for clinical use. Currently, none of these new agents has a specific antidote, and little advise can be given on how to manage a major bleeding event. The aim of this article is to describe the haemorrhagic risk and the management of bleeding complications associated with the principal anticoagulant drugs.

Keywords: Anticoagulants, bleeding, vitamin k antagonists, dabigatran, rivaroxaban, heparin, fondaparinux, venous thromboembolism, anticoagulant therapy, heparins, transfusion, Thrombosis, Hemostasis, Interna-tional normalized Ratio, VKA, hepatic disease, hypertension, malignancy, haematological disease, thromboembolic risk, VKAs therapy, INR monitoring, American College of Chest Physicians, warfarin therapy, acenocoumarol, phenopro-coumon, Antifibrinolytic drugs, tranexamic acid, fresh frozen plasma, recombinant factor VIIa, Prothrombin Complex Concentrates, liver disease, haemophilia, anti-Xa activity, Protamine Sulfate

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2010
Page: [3478 - 3482]
Pages: 5
DOI: 10.2174/138161210793563329
Price: $65

Article Metrics

PDF: 8